Clinical Trials Logo

Enterovirus Infection clinical trials

View clinical trials related to Enterovirus Infection.

Filter by:
  • Completed  
  • Page 1

NCT ID: NCT02961595 Completed - Type 1 Diabetes Clinical Trials

Live Enterovirus Vaccine and Type 1 Diabetes

Start date: October 1999
Phase: Phase 1
Study type: Interventional

Enterovirus infections may either increase or decrease the risk of type 1 diabetes depending on the age of infection and the type of enterovirus in question. This study evaluated whether early serial exposures to three replication-competent enterovirus strains (live poliovirus vaccine, OPV) can influence the immunity to other enteroviruses and the possible initiation of autoantibodies e.g. islet autoimmunity in young genetically predisposed children.

NCT ID: NCT01268787 Completed - Clinical trials for Enterovirus Infection

A Study to Evaluate the Safety and Immunogenicity of EV71 Vaccine

Start date: December 2010
Phase: Phase 1
Study type: Interventional

This study is aims to evaluate the safety, reactogenicity and immunogenicity of EV71 vaccine at a 0.25ml or 0.5ml dose in health volunteers

NCT ID: NCT00031512 Completed - Clinical trials for Enterovirus Infection

Pleconaril Enteroviral Sepsis Syndrome

Start date: June 27, 2001
Phase: Phase 2
Study type: Interventional

A common group of viruses that infect humans are enteroviruses. Enteroviruses produce illnesses in children which may range from very mild (summer colds) to severe (infections of the brain, liver, and heart). The purpose of this study is to determine if a new drug called pleconaril helps treat babies with enteroviral sepsis. In addition, researchers are attempting to determine a safe and effective dose of pleconaril to help babies with this disease. Infants who are 15 days or younger when diagnosed with enteroviral disease are eligible for this study. Two out of 3 babies will be randomly assigned to receive Pleconaril and the other one out of three will receive a placebo (inactive substitute). Participants will be hospitalized while receiving study medication. Babies will receive standard treatment care for their symptoms and will be observed for their medical progress. Participants may be in the study for up to 2 years.